

August 7, 2017

**IMPORTANT PRESCRIBING INFORMATION**

**Subject: DepoCyt® (cytarabine liposome injection) Drug Discontinuation**

Dear Health Care Provider:

The purpose of this letter is to inform you that Pacira Pharmaceuticals, Inc., disclosed that they will discontinue all future manufacturing and supply of DepoCyt® (cytarabine liposome injection) NDC 57665-331-01. At the current rate of distribution, Leadiant Biosciences, Inc., will be out of stock of DepoCyt® by mid-August, 2017.

**Information Regarding Drug Discontinuation**

The reason for the discontinuation of DepoCyt® was due to manufacturing challenges. Pacira Pharmaceuticals has no plans to resume manufacturing of DepoCyt®.

The supply of DepoCyt® in distribution is expected to be out of stock by mid-August. Once the current supply is depleted, Leadiant Biosciences will be out of stock indefinitely.

Please refer to the FDA drug shortage website information at <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm#dD> for up to date information.

Should you have any clinical or medical questions regarding the use of DepoCyt®, please contact Leadiant Biosciences Medical Affairs at (866) 634-2765 or [Leadiant@tmacmail.com](mailto:Leadiant@tmacmail.com).

Sincerely,



Joseph M. Wiley, MD, FAAP  
Vice President, Medical Affairs, Drug Safety and Pharmacovigilance  
Leadiant Biosciences, Inc.  
9841 Washingtonian Boulevard  
Gaithersburg, MD 20878

Enclosure(s): DepoCyt® (cytarabine liposome injection) Full prescribing information